Teleflex Incorporated (NYSE:TFX) Receives Average Recommendation of “Moderate Buy” from Brokerages

Teleflex Incorporated (NYSE:TFX – Get Rating) has been given an average rating of “Moderate Buy” by the fifteen brokerages that are currently covering the company, MarketBeat reports. Six research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $279.62.

A number of equities analysts have issued reports on TFX shares. Mizuho began coverage on Teleflex in a report on Wednesday, October 26th. They issued a “neutral” rating and a $220.00 target price for the company. Raymond James cut their target price on shares of Teleflex from $266.00 to $231.00 and set an “outperform” rating on the stock in a research note on Friday, October 28th. Piper Sandler decreased their price objective on Teleflex from $265.00 to $245.00 in a report on Thursday, October 27th. Stephens upped their target price on shares of Teleflex from $280.00 to $295.00 and gave the stock an “overweight” rating in a report on Wednesday, December 28th. Finally, Jefferies Financial Group initiated coverage on shares of Teleflex in a report on Wednesday, October 12th. They set a “hold” rating and a $210.00 price objective on the stock.

Teleflex Stock Down 1.1 %

Shares of TFX opened at $235.62 on Wednesday. The company has a current ratio of 2.39, a quick ratio of 1.52 and a debt-to-equity ratio of 0.41. Teleflex has a 12 month low of $182.65 and a 12 month high of $356.72. The firm’s 50 day moving average is $240.59 and its 200-day moving average is $230.98. The stock has a market capitalization of $11.05 billion, a PE ratio of 27.02, a P/E/G ratio of 2.66 and a beta of 1.04.

Teleflex (NYSE:TFX – Get Rating) last posted its quarterly earnings results on Thursday, October 27th. The medical technology company reported $3.27 EPS for the quarter, topping analysts’ consensus estimates of $3.10 by $0.17. The company had revenue of $686.80 million during the quarter, compared to analysts’ expectations of $691.52 million. Teleflex had a return on equity of 16.26% and a net margin of 14.76%. Teleflex’s revenue was down 1.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.51 EPS. Equities research analysts forecast that Teleflex will post 12.98 EPS for the current year.

Teleflex Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, December 15th. Shareholders of record on Tuesday, November 15th were paid a $0.34 dividend. The ex-dividend date of this dividend was Monday, November 14th. This represents a $1.36 dividend on an annualized basis and a yield of 0.58%. Teleflex’s dividend payout ratio (DPR) is currently 15.60%.

Hedge Funds Weigh In On Teleflex

Hedge funds have recently made changes to their positions in the business. Investors Asset Management of Georgia Inc. GA ADV bought a new stake in shares of Teleflex during the second quarter valued at approximately $25,000. Clear Street Markets LLC increased its position in shares of Teleflex by 426.3% during the second quarter. Clear Street Markets LLC now owns 100 shares of the medical technology company’s stock valued at $25,000 after acquiring an additional 81 shares in the last quarter. General Partner Inc. purchased a new position in Teleflex in the 4th quarter worth approximately $28,000. Hallmark Capital Management Inc. purchased a new stake in Teleflex during the 2nd quarter valued at $31,000. Finally, Glassman Wealth Services lifted its holdings in shares of Teleflex by 271.4% during the second quarter. Glassman Wealth Services now owns 130 shares of the medical technology company’s stock valued at $32,000 after purchasing an additional 95 shares in the last quarter. 93.82% of the stock is owned by hedge funds and other institutional investors.

About Teleflex

(Get Rating)

Teleflex, Inc provides medical technology products which enables healthcare providers to improve patient outcomes and enhance patient and provider safety. The firm designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications.